deltatrials
Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT07446491

A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

A Phase Ib/II Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Characteristics of a Single Subcutaneous Injection of Polyethylene Glycolated Thrombopoietin Peptide (PN20) in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd.

Conditions Thrombocytopenia Associated With Chronic Liver Disease
Interventions PN20 Placebo
Updated 1 time since 2026 Last updated: Feb 26, 2026 Started: Jun 6, 2025 Primary completion: May 30, 2026 Completion: Jun 28, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07446491, this PHASE1/PHASE2 trial focuses on Thrombocytopenia Associated With Chronic Liver Disease and remains actively recruiting participants. Sponsored by Chongqing Peg-Bio Biopharm Co., Ltd., it has been updated 1 time since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Mar 2026 – present · 6 months · monthly snapshotRecruiting

Change History

1 version recorded
Recruiting — PHASE1/PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Chongqing Peg-Bio Biopharm Co., Ltd.
Data source: Chongqing Peg-Bio Biopharm Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations